GenSight Biologics Future Growth
Future criteria checks 2/6
GenSight Biologics's earnings are forecast to decline at 49% per annum while its annual revenue is expected to grow at 33.5% per year. EPS is expected to decline by 57% per annum.
Key information
-49.0%
Earnings growth rate
-57.0%
EPS growth rate
| Biotechs earnings growth | 10.3% |
| Revenue growth rate | 33.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 19 Dec 2024 |
Recent future growth updates
Recent updates
Is There An Opportunity With GenSight Biologics S.A.'s (EPA:SIGHT) 30% Undervaluation?
Dec 22
Is GenSight Biologics S.A. (EPA:SIGHT) Trading At A 39% Discount?
Sep 20Health Check: How Prudently Does GenSight Biologics (EPA:SIGHT) Use Debt?
Aug 17Rock star Growth Puts GenSight Biologics (EPA:SIGHT) In A Position To Use Debt
Aug 04GenSight Biologics S.A. (EPA:SIGHT) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 14GenSight Biologics S.A. (EPA:SIGHT): Is Breakeven Near?
May 10Analysts Expect Breakeven For GenSight Biologics S.A. (EPA:SIGHT) Before Long
Feb 02A Quick Analysis On GenSight Biologics' (EPA:SIGHT) CEO Salary
Dec 09
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 6 | -66 | -64 | -64 | 1 |
| 12/31/2025 | 7 | -36 | -34 | -34 | 2 |
| 12/31/2024 | 5 | -25 | -22 | -22 | 2 |
| 6/30/2024 | 2 | -20 | -16 | -16 | N/A |
| 3/31/2024 | 2 | -23 | -20 | -20 | N/A |
| 12/31/2023 | 3 | -26 | -25 | -25 | N/A |
| 9/30/2023 | 3 | -28 | -29 | -29 | N/A |
| 6/30/2023 | 3 | -29 | -33 | -33 | N/A |
| 3/31/2023 | 4 | -28 | -34 | -34 | N/A |
| 12/31/2022 | 5 | -28 | -34 | -34 | N/A |
| 9/30/2022 | 5 | -29 | -29 | -29 | N/A |
| 6/30/2022 | 5 | -31 | -24 | -24 | N/A |
| 3/31/2022 | 6 | -30 | -20 | -20 | N/A |
| 12/31/2021 | 8 | -29 | -17 | -17 | N/A |
| 9/30/2021 | 9 | -28 | -18 | -18 | N/A |
| 6/30/2021 | 11 | -28 | -19 | -19 | N/A |
| 3/31/2021 | 9 | -31 | -17 | -17 | N/A |
| 12/31/2020 | 7 | -34 | -15 | -15 | N/A |
| 9/30/2020 | 7 | -31 | -15 | -15 | N/A |
| 6/30/2020 | 6 | -28 | -15 | -15 | N/A |
| 3/31/2020 | 5 | -30 | -22 | -22 | N/A |
| 12/31/2019 | 5 | -31 | -28 | -28 | N/A |
| 9/30/2019 | 5 | -35 | -32 | -31 | N/A |
| 6/30/2019 | 5 | -39 | -35 | -35 | N/A |
| 3/31/2019 | 5 | -36 | -32 | -32 | N/A |
| 12/31/2018 | 4 | -33 | -29 | -28 | N/A |
| 9/30/2018 | 4 | -30 | -25 | -25 | N/A |
| 6/30/2018 | 4 | -26 | -21 | -21 | N/A |
| 3/31/2018 | 4 | -25 | N/A | -20 | N/A |
| 12/31/2017 | 4 | -24 | N/A | -19 | N/A |
| 9/30/2017 | 3 | -23 | N/A | -19 | N/A |
| 6/30/2017 | 3 | -23 | N/A | -20 | N/A |
| 3/31/2017 | 3 | -22 | N/A | -20 | N/A |
| 12/31/2016 | 3 | -22 | N/A | -20 | N/A |
| 9/30/2016 | 3 | -20 | N/A | -18 | N/A |
| 6/30/2016 | 4 | -18 | N/A | -17 | N/A |
| 3/31/2016 | 4 | -16 | N/A | -15 | N/A |
| 12/31/2015 | 4 | -14 | N/A | -12 | N/A |
| 9/30/2015 | 3 | -11 | N/A | -10 | N/A |
| 6/30/2015 | 2 | -9 | N/A | -7 | N/A |
| 3/31/2015 | 2 | -8 | N/A | -6 | N/A |
| 12/31/2014 | 1 | -7 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SIGHT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SIGHT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SIGHT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SIGHT's revenue (33.5% per year) is forecast to grow faster than the French market (5.5% per year).
High Growth Revenue: SIGHT's revenue (33.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SIGHT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 09:04 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GenSight Biologics S.A. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ingrid Gafanhão | Bryan Garnier & Co |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Daniil Gataulin | Chardan Capital Markets, LLC |